Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

NCT05171075 is registered in ClinicalTrials.gov with Anthos Therapeutics, Inc. as lead sponsor.

NCT NCT05171075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05171075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE
Lead sponsor
Anthos Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
September 27, 2022
Completion date
April 10, 2026
Enrollment
417 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

deep venous thrombosis, pulmonary embolism, venous thromboembolism